EyePoint announces strategic prioritization
EYPT•EyePoint will focus on Duravya for DME, end its phase 3 wet AMD trials early and reduce its workforce by about 53%, targeting about $30 million in annualized savings.
1. Pipeline and workforce changes
EyePoint said it will prioritize Duravya for DME and end its phase 3 wet AMD trials early. Phase 3 data for DME are expected in the fourth quarter of 2027. The board approved a workforce reduction of about 53%, expected to occur in the fourth quarter of 2026 and be completed in the first half of 2027; the company estimates about $30 million in annualized savings and about $9 million in employee separation charges.
